
Please try another search
Gilead Sciences (NASDAQ:GILD) reported its Q1 results, with EPS of $2.12 coming in better than the consensus estimate of $1.81. Revenue grew 3% year-over-year to $6.6 billion, compared to the consensus estimate of $6.28 billion.
Biktarvy sales rose 18% to $2.2 billion, Descovy sales rose 4%, and Truvada sales declined 72% year-over-year in Q1.
The company expects Q2/22 EPS in the range of $6.20-$6.70, compared to the consensus of $6.50, and revenue in the range of $23.8-24.3 billion, compared to the consensus of $24.48 billion. The company sees product sales between $23.8 billion and $24.3 billion, which includes $2 billion in Veklury sales.
Shares of Gilead were down 15% year-to-date going into the earnings results.
By Davit Kirakosyan
Hong Kong’s benchmark Hang Seng Index opened lower on Monday, down 0.78% at press time, as a better-than-expected July jobs report in the U.S. intensified fears of aggressive...
Major coins were buoyant Sunday evening as the global cryptocurrency market cap rose 0.9% to $1.1 trillion at press time. Price Performance Of Major...
By Ambar Warrick Investing.com-- Australian copper miner OZ Minerals Ltd (ASX:OZL) rejected an 8.4 billion Australian dollar ($5.8 billion) takeover offer from BHP Group...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.